Skip to main content
. 2015 Dec 10;7(3):3144–3157. doi: 10.18632/oncotarget.6551

Figure 3. PAD4 promotes leukemia cell differentiation and ATRA treatment facilitates its nucleus translocation.

Figure 3

(A) Efficiency of siRNA transfection targeting PAD4 was validated by Western blot in the absence or presence of ATRA exposure. (B) The differentiation of HL-60 cells after silencing B1–B6 or over-expressing B7–B12 were detected by Flow cytometry. The effect of PAD4 inhibitor, Cl-amidine, on the differentiation of HL-60 cells were also detected by FCM B13–B16. *P < 0.05, **P < 0.01. Data are means of biological triplicates (± standard error). (C) After treatment with ATRA for various times, the PAD4 expression in cytoplasm (left) and nucleus (right) at protein level was detected by Western blot. Tubulin and Lamin B were applied as loading controls, respectively. (D) PAD4 immunostaining (visualized in green) in HL-60 before and after ATRA treatment was assayed by immuno-fluorescent method. All data are representative of triplicate experiments.